ZBHHealthcare · Medical DevicesThe 27 Wall Street analysts covering Zimmer Biomet Holdings, Inc. hold a median 12-month price target of $106 — +5.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 91 of 100 as at 15 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Zimmer Biomet Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (96): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Momentum (54): The shares have been drifting down relative to others.
Size (11): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ZBH, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +5.3% from it.
Of the 20 most recent actions, 6 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Aug 2026 | Canaccord Genuity | Maintains | Hold | $83 → $100 |
| 7 Aug 2026 | Truist Securities | Maintains | Hold | $92 → $106 |
| 6 Aug 2026 | Bernstein | Maintains | Market Perform | $91 → $93 |
| 6 Aug 2026 | RBC Capital | Maintains | Outperform | $101 → $110 |
| 6 Aug 2026 | Stifel | Maintains | Buy | $105 → $110 |
| 28 July 2026 | UBS | Assumes | Buy | $89 → $115 |
| 9 July 2026 | BMO Capital | Initiates | Market Perform | $95 |
| 9 July 2026 | BMO Capital | Initiates | Market Perform | — |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | $120 → $110 |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 28 May 2026 | Citigroup | Maintains | Neutral | — |
| 29 Apr 2026 | Barclays | Maintains | Underweight | — |
| 29 Apr 2026 | Citigroup | Maintains | Neutral | — |
| 29 Apr 2026 | Citizens | Maintains | Market Outperform | — |
| 29 Apr 2026 | JP Morgan | Maintains | Neutral | — |
| 29 Apr 2026 | Stifel | Maintains | Buy | — |
| 29 Apr 2026 | Truist Securities | Reiterates | Hold | — |
| 29 Apr 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 13 Apr 2026 | Leerink Partners | Initiates | Market Perform | — |
| 23 Mar 2026 | BTIG | Downgrade | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ZBH appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 33% of US stocks
Cheaper than 50% of US stocks
Cheaper than 56% of US stocks
Cheaper than 38% of US stocks
Higher than 39% of US stocks
Higher than 66% of US stocks
Higher than 83% of US stocks
Higher than 76% of US stocks
Higher than 69% of US stocks
Higher than 56% of US stocks
Higher than 71% of US stocks
Higher than 22% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Zimmer Biomet Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research highlights Zimmer Biomet (ZBH) as a strong momentum stock, using its Zacks Style Scores framework to identify the company as a favorable pick for momentum-focused investors.
Why it matters — ZBH watchers would care because being highlighted as a strong momentum stock could draw increased investor attention to the company's shares.
Zimmer Biomet reported second-quarter 2026 net sales of $2.177 billion, up 4.8% on a reported basis and 4.0% on an organic constant-currency basis. Growth in hips, specialty businesses and technology helped offset weaker performance in certain other product lines.
Why it matters — The results give ZBH watchers a reading on recent sales momentum and which product areas are driving or dragging growth.
Zacks Investment Research highlights Zimmer Biomet (ZBH) as a strong value stock, citing its Zacks Style Scores as a method for identifying potentially market-beating stocks.
Why it matters — ZBH watchers would care because the report positions the company favorably among value-oriented investment criteria, suggesting it may be viewed attractively by value-focused investors.
Seeking Alpha published the Q2 2026 earnings call transcript for Zimmer Biomet Holdings, Inc. (ZBH). The transcript covers the company's second-quarter 2026 earnings call.
Why it matters — A ZBH watcher would read the transcript for management commentary on the company's quarterly results and outlook directly from the earnings call.
Zimmer Biomet Holdings beat second-quarter earnings and revenue estimates and raised its 2026 outlook, leading to pre-market gains despite pressure on adjusted margins.
Why it matters — The earnings beat and raised outlook signal stronger-than-expected financial performance, which could influence investor perception of the company's near-term trajectory.
The 27 Wall Street analysts covering Zimmer Biomet Holdings, Inc. have a median 12-month price target of $106, with estimates ranging from $93 to $130. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 27 analysts covering Zimmer Biomet Holdings, Inc., 9 rate it a Buy, 18 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Zimmer Biomet Holdings, Inc. 91 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Aug 2026, Zimmer Biomet Holdings, Inc. ranks 91 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (96 of 100).
No one can know that. What the data says: the median 12-month target from 27 analysts implies +5.3% from the last close, and Ticker Nerd's factor model ranks Zimmer Biomet Holdings, Inc. 91 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Zimmer Biomet Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ZBH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $93 to $130 over the next 12 months.
Zimmer Biomet Holdings, Inc. returned -0.4% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Zimmer Biomet Holdings, Inc. is a medical device company specializing in musculoskeletal healthcare solutions.
The most recent item we track (Zacks Investment Research, 10 Aug 2026): "Here's Why Zimmer Biomet (ZBH) is a Strong Momentum Stock". Zacks Investment Research highlights Zimmer Biomet (ZBH) as a strong momentum stock, using its Zacks Style Scores framework to identify the company as a favorable pick for momentum-focused investors.
Zimmer Biomet Holdings, Inc. is a medical device company specializing in musculoskeletal healthcare solutions. The company designs, manufactures, and markets orthopedic reconstructive implants for hips, knees, and shoulders, along with a broad range of products for sports medicine, extremities, and trauma surgery. Its portfolio also includes surgical tools, biologics, and digital and robotic technologies that support orthopedic procedures and post-operative care. Zimmer Biomet serves hospitals, ambulatory surgery centers, and healthcare professionals worldwide, focusing on products that enable joint replacement, bone repair, and improved mobility for patients. Following the spin-off of its dental and spine businesses, the company is concentrated on large joint reconstruction and related musculoskeletal products as core areas of activity. Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet holds a significant position in the global orthopedic market, particularly in the United States, Europe, and Japan, where it is a key supplier to orthopedic surgeons and healthcare systems.
CEO Mr. Ivan Tornos · 17,000 employees · United States · https://www.zimmerbiomet.com